<DOC>
	<DOC>NCT00750334</DOC>
	<brief_summary>This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.</brief_summary>
	<brief_title>A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Provide signed, written informed consent. Be at least 18 years old. Have a pathologically confirmed MDS and score according to the IPSS at study entry. Pathologic confirmation is the responsibility of the investigator. Have been treated previously for MDS as follow: a.Patients must have had at least 1, but no more than 2, prior treatment regimens; b.Patients must not have refractory (i.e., disease progression or no evidence of response while on treatment) to more than 1 prior treatment regimen. Have Eastern Cooperative Oncology Group (ECOG) performance status of 02 Be able to comply with study procedures and followup examinations. Have adequate hepatic and renal function. Be nonfertile or agree to use birth control during the study through the end of the last treatment visit and at least 90 days after. Have had a readjustment of dose and/or schedule of erythropoietin, granulocyte colony stimulating factor(GCSF) or other growth factors within 8 weeks prior to the first dose of oral clofarabine. Have had any other chemotherapy or any investigational therapy for MDS within 4 weeks of the first dose of oral clofarabine. Have not recovered to â‰¤ Grade 2 in severity of any drugrelated nonhematologic toxicity prior to the first dose of oral clofarabine. Have an uncontrolled systemic fungal, bacterial, viral or other infection. Have a history of serious disease involving the heart. Have a clinically significant cardiac assessment at screening or a known family history QT prolongation. Currently uses a medication known to prolong the QT interval. Have had any prior treatment with clofarabine (IV or oral). Have had a diagnosis of another malignancy, unless the patient has been disease free for at least 3 years after completing curative intent therapy except for the following: a. Patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the diseasefree duration, are eligible for this study if definitive treatment or the condition has been completed. b. Patients with organconfined prostate cancer with no evidence of recurrent or progressive disease based on prostate specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed. Have prior positive test for the human immunodeficiency virus (HIV). Have gastrointestinal disease or prior surgery, which may affect the ability of the patient to absorb oral clofarabine. Is currently participating in another concurrent investigational protocol that is not restricted to data and/or sample collection for patient demographic and/or disease purposes.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Oral Clofarabine,</keyword>
	<keyword>relapsed/refractory MDS,</keyword>
	<keyword>Myelodysplastic</keyword>
</DOC>